NCT05902871Active, not recruiting
Direct Selective Laser Trabeculoplasty in Ethnic Chinese Population
Direct Selective Laser Trabeculoplasty for Primary Open Angle Glaucoma and Ocular Hypertension and Normal Tension Glaucoma in Ethnic Chinese Population - The Zhuiguangzhe Trial
Source: ClinicalTrials.gov · Last updated 17 Aug 2026
Brief summary (registry, in English)
The objective of this study is to evaluate the safety and effectiveness of Direct Selective Laser Trabeculoplasty (DSLT) in ethnic Chinese participants with Primary Open Angle Glaucoma (POAG), Ocular Hypertension (OHT), or Normal Tension Glaucoma (NTG).
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 40 (actual)
- First submitted
- 10 May 2023
- Start date
- 11 Mar 2024
- Primary completion date
- 2 Jul 2026
- Lead sponsor
- BelkinVision
- Diseases
- Glaucoma, High blood pressure
- NCT number
- NCT05902871
What you commit to
- Study type: Interventional
- Participants enrolled: 40
- From 11 Mar 2024 to the primary completion date, 2 Jul 2026
- 2 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of medications as specified in the protocol.
- Prior surgery in the study eye.
Other illness
- Eye conditions as specified in the protocol.
Other
- Unable to provide a reliable visual field test.
- Women who are pregnant or may become pregnant during the study.
- In a vision-dependent profession such as pilot or commercial driver.
- Other protocol-specified exclusion criteria may apply.
Who the study is looking for
- Chinese ethnicity with corrected visual acuity greater than 6/18 in both eyes.
- Diagnosed with mild to moderate primary open angle glaucoma, ocular hypertension, or normal tension open angle glaucoma.
- Willing and able to participate in a 12-month study, comply with the study procedures, and adhere to the follow-up schedule.
- Capable of giving informed consent.
- Other protocol-specified inclusion criteria may apply.
Age in the registry: 21 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| C-Mer Eye Clinic Coordinator of this site? Confirm its status | Hong Kong | China | Unknown status |
| SERI Coordinator of this site? Confirm its status | Singapore | Singapore | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.